Shabbir Muhammad Asim, Tiwari Nidhish, Burdorf Adam, Moulton Michael, Velagapudi Poonam
Division of Cardiovascular Medicine, University of Nebraska Medical Center, 42nd and Emile St, Omaha, NE 68198, USA.
Division of Cardiothoracic Surgery, University of Nebraska Medical Center, 42nd and Emile St, Omaha, NE 68198, USA.
Eur Heart J Case Rep. 2023 Jun 7;7(6):ytad240. doi: 10.1093/ehjcr/ytad240. eCollection 2023 Jun.
Cardiogenic shock (CS) associated with severe mitral regurgitation (MR) forebodes a high risk of morbidity and mortality. Transcatheter edge-to-edge repair (TEER) is a rapidly evolving technique for severe MR in haemodynamically stable patients. However, the safety and efficacy of TEER for severe MR in CS are not well established.
An 83-year-old male presented with dyspnoea and was hospitalized for heart failure. Chest X-ray revealed pulmonary oedema. Transthoracic echocardiography showed severely depressed ejection fraction (EF) with severe secondary MR. Right heart catheterization confirmed a low cardiac index. Diuretics and inotropes were administered. Due to persistent hypotension, we could not wean inotropes. The patient was deemed high risk for surgery by the heart team, and a decision was made to proceed with TEER with MitraClip. Under transoesophageal echocardiography and fluoroscopic guidance, two MitraClips were deployed sequentially. The MR grade was reduced to two mild jets subsequently. The patient was weaned off inotropes and eventually discharged. At the 30-day follow-up, he was participating in physical activities such as golf.
Cardiogenic shock complicated by severe MR carries high mortality. With severe MR, the forward stroke volume is lower than the stated EF leading to poor organ perfusion. Inotropes and/or mechanical circulatory support devices are paramount for initial stabilization; however, they do not treat underlying MR. Transcatheter edge-to-edge repair with MitraClip has been shown to improve survival in CS patients with severe MR in observational studies. However, prospective trials are lacking. Our case demonstrates the utility of MitraClip to treat severe secondary MR refractory to medical therapy in a CS patient. The heart team must evaluate risks and benefits of this therapy in CS patients.
与严重二尖瓣反流(MR)相关的心源性休克(CS)预示着高发病率和死亡率风险。经导管缘对缘修复术(TEER)是一种用于血流动力学稳定的严重MR患者的快速发展的技术。然而,TEER治疗CS中严重MR的安全性和有效性尚未明确。
一名83岁男性因呼吸困难入院治疗心力衰竭。胸部X线显示肺水肿。经胸超声心动图显示射血分数(EF)严重降低并伴有严重继发性MR。右心导管检查证实心脏指数低。给予利尿剂和正性肌力药物。由于持续低血压,无法停用正性肌力药物。心脏团队认为该患者手术风险高,决定采用MitraClip进行TEER。在经食管超声心动图和荧光透视引导下,依次部署了两个MitraClip。随后MR分级降至两个轻度反流束。患者停用正性肌力药物,最终出院。在30天随访时,他正在参与如打高尔夫球等体育活动。
并发严重MR的心源性休克死亡率高。存在严重MR时,前向搏出量低于所述EF,导致器官灌注不良。正性肌力药物和/或机械循环支持装置对于初始稳定至关重要;然而,它们并不能治疗潜在的MR。在观察性研究中,使用MitraClip进行经导管缘对缘修复已显示可改善严重MR的CS患者的生存率。然而,缺乏前瞻性试验。我们的病例证明了MitraClip在治疗CS患者中对药物治疗难治的严重继发性MR的效用。心脏团队必须评估CS患者中这种治疗的风险和益处。